| 摘要 |
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds of formulawhere Rand Rare independently selected from the group of -C-C-alkyl, -C-C-haloalkyl, -CN, -F, -Cl, -Br and -I; Ris independently selected from the group of -C-C-alkyl, -C-C-haloalkyl, -CN, -F, -Cl and -I; Ris independently selected from the group of -C-C-alkyl, -C-C-alkenyl, -C-C-alkynyl and a group containing up to 20 carbon atoms and containing at least one double bond and at least one triple bond; and all salts, stereoisomers, mixtures of stereoisomers, prodrugs, metabolites, solvates, and hydrates thereof, useful in the methods of the invention. Energy biomarkers, in particular, Co Q10, useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. |
